| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2022 | 27.91% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
| 09/09/2022 | 16.28% | Mizuho | $26 → $30 | Maintains | Buy |
| 09/09/2022 | 35.66% | Barclays | $22 → $35 | Maintains | Overweight |
| 09/09/2022 | 12.4% | HC Wainwright & Co. | $25 → $29 | Maintains | Buy |
| 09/09/2022 | 35.66% | Needham | $25 → $35 | Maintains | Buy |
| 08/25/2022 | -6.98% | Wells Fargo | $17 → $24 | Maintains | Equal-Weight |
| 10/26/2021 | -14.73% | Barclays | $33 → $22 | Maintains | Overweight |
| 10/25/2021 | -34.11% | Wells Fargo | → $17 | Downgrades | Overweight → Equal-Weight |
| 10/18/2021 | -3.1% | Needham | $45 → $25 | Maintains | Buy |
| 10/18/2021 | -30.23% | HC Wainwright & Co. | $26 → $18 | Maintains | Buy |
| 10/13/2021 | 0.78% | HC Wainwright & Co. | $35 → $26 | Maintains | Buy |
| 08/06/2021 | 27.91% | Barclays | $32 → $33 | Maintains | Overweight |
| 02/23/2021 | 35.66% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
| 01/08/2021 | 74.42% | Needham | $42 → $45 | Maintains | Buy |
| 10/15/2020 | 62.79% | Needham | $36 → $42 | Maintains | Buy |
| 04/16/2020 | 20.16% | Stifel | $35 → $31 | Maintains | Buy |
| 04/01/2020 | 35.66% | Mizuho | $39 → $35 | Maintains | Buy |
| 03/27/2020 | -6.98% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
| 03/23/2020 | -41.86% | Goldman Sachs | $32 → $15 | Downgrades | Buy → Neutral |
| 02/25/2020 | 55.04% | Piper Sandler | $37 → $40 | Reiterates | → Overweight |
| 02/25/2020 | 39.53% | Needham | $32 → $36 | Maintains | Buy |
| 02/18/2020 | 43.41% | Piper Sandler | $38 → $37 | Maintains | Overweight |
| 01/23/2020 | 51.16% | Mizuho | $34 → $39 | Maintains | Buy |
| 12/02/2019 | -3.1% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/30/2019 | -22.48% | Wells Fargo | $12.5 → $20 | Upgrades | Market Perform → Outperform |
| 06/11/2019 | 8.53% | Barclays | → $28 | Initiates Coverage On | → Overweight |
| 02/15/2019 | — | Wells Fargo | Initiates Coverage On | → Market Perform | |
| 02/14/2019 | -3.1% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 01/29/2019 | 93.8% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 11/16/2018 | 58.91% | Guggenheim | → $41 | Upgrades | Neutral → Buy |
| 09/17/2018 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 03/05/2018 | 132.56% | Goldman Sachs | → $60 | Initiates Coverage On | → Buy |
| 01/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 12/06/2017 | 62.79% | Guggenheim | → $42 | Initiates Coverage On | → Buy |
| 11/27/2017 | 20.16% | Barclays | → $31 | Initiates Coverage On | → Overweight |
| 11/17/2017 | 43.41% | Mizuho | → $37 | Initiates Coverage On | → Buy |
Revance Therapeutics Questions & Answers
The latest price target for Revance Therapeutics (NASDAQ: RVNC) was reported by Goldman Sachs on September 22, 2022. The analyst firm set a price target for $33.00 expecting RVNC to rise to within 12 months (a possible 27.91% upside). 11 analyst firms have reported ratings in the last year.
The latest analyst rating for Revance Therapeutics (NASDAQ: RVNC) was provided by Goldman Sachs, and Revance Therapeutics initiated their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revance Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revance Therapeutics was filed on September 22, 2022 so you should expect the next rating to be made available sometime around September 22, 2023.
While ratings are subjective and will change, the latest Revance Therapeutics (RVNC) rating was a initiated with a price target of $0.00 to $33.00. The current price Revance Therapeutics (RVNC) is trading at is $25.80, which is within the analyst's predicted range.